Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients

Brain and Behavior

Volumn 5, Issue 1, 2015, Pages 39-44

  Hall, Kathryn T ^a   Tolkin, Benjamin R ^a   Chinn, Garrett M ^b   Kirsch, Irving ^a,c   Kelley, John M ^a,b,d   Lembo, Anthony J ^a   Kaptchuk, Ted J ^a   Kokkotou, Efi ^a   Davis, Roger B ^a   Conboy, Lisa A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

^d ENDICOTT COLLEGE   (United States)

Author keywords

COMT; Catechol O methyltransferase; Complaints; Conscientiousness; Personality

Indexed keywords

CATECHOL METHYLTRANSFERASE; GENOMIC DNA; PLACEBO;

ADULT; AGREEABLENESS; ALLELE; ANXIETY; ARTICLE; BECK ANXIETY INVENTORY; BEHAVIOR CHANGE; CATECHOL METHYLTRANSFERASE GENE; CONSCIENTIOUSNESS; CONTROLLED STUDY; EXTRAVERSION; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NEUROSIS; OPENNESS; PERSONALITY; PERSONALITY DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF-RATING ANXIETY SCALE; SEVERITY OF ILLNESS INDEX; SOCIAL PSYCHOLOGY; SOMATIZATION; COMPLICATION; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY;

ADULT; ANXIETY; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENETIC VARIATION; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PERSONALITY; PLACEBOS;

EID: 84922632614     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.294     Document Type: Article

References (32)

1. Amanzio, M., L. L. Corazzini, L. Vase, and F. Benedetti. 2009. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 146:261-269.
2. Aoki, J., K. Iwahashi, J. Ishigooka, and K. Ikeda. 2011. Association study on catechol-O-methyltransferase (COMT) Val158Met gene polymorphism and NEO-FFI. Psychiatry Res. 187:312-313.
3. Barsky, A. J., R. Saintfort, M. P. Rogers, and J. F. Borus. 2002. Nonspecific medication side effects and the nocebo phenomenon. JAMA 287:622-627.
4. Beck, A. T., N. Epstein, G. Brown, and R. A. Steer. 1988. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 56:893-897.
5. Conboy, L. A., R. H. Wasserman, E. E. Jacobson, R. B. Davis, A. T. Legedza, M. Park, et al. 2006. Investigating placebo effects in irritable bowel syndrome: a novel research design. Contemp. Clin. Trials. 27:123-134.
6. Costa, P. T. Jr, and R. R. McCrae. 1987. Personality assessment in psychosomatic medicine. Value of a trait taxonomy. Adv. Psychosom. Med. 17:71-82.
7. Costa, P. T. Jr, A. Terracciano, and R. R. McCrae. 2001. Gender differences in personality traits across cultures: robust and surprising findings. J. Pers. Soc. Psychol. 81:322-331.
8. Diatchenko, L., A. G. Nackley, G. D. Slade, K. Bhalang, I. Belfer, M. B. Max, et al. 2006. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 125:216-224.
9. Eisenberg, L. 1980. What makes persons "patients" and patients "well? Am. J. Med. 69:277-286.
10. Francis, C. Y., J. Morris, and P. J. Whorwell. 1997. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 11:395-402.
11. Gorsuch, R. L. 1983. Factor analysis. L. Erlbaum Associates, Hillsdale, NJ.
12. Hall, K. T., A. J. Lembo, I. Kirsch, D. C. Ziogas, J. Douaiher, K. B. Jensen, et al. 2012. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 7:e48135.
13. Hall, K. T., C. P. Nelson, R. B. Davis, J. E. Buring, I. Kirsch, M. A. Mittleman, et al. 2014. Polymorphisms in catechol-o-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 34:2160-2167.
14. Hyphantis, T. N., T. C. Taunay, D. S. Macedo, M. G. Soeiro-de-Souza, L. W. Bisol, K. N. Fountoulakis, et al. 2013. Affective temperaments and ego defense mechanisms associated with somatic symptom severity in a large sample. J. Affect. Disord. 150:481-489.
15. Jylha, P., and E. Isometsa. 2006. The relationship of neuroticism and extraversion to symptoms of anxiety and depression in the general population. Dep. Anxiety 23:281-289.
16. Kanasaki, K., K. Palmsten, H. Sugimoto, S. Ahmad, Y. Hamano, L. Xie, et al. 2008. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 453:1117-1121.
17. Kaptchuk, T. J., J. M. Kelley, L. A. Conboy, R. B. Davis, C. E. Kerr, E. E. Jacobson, et al. 2008. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336:999-1003.
18. Karvonen, J. T., J. Veijola, L. Kantojarvi, J. Miettunen, J. Ekelund, D. Lichtermann, et al. 2006. Temperament profiles and somatization-an epidemiological study of young adult people. J. Psychosom. Res. 61:841-846.
19. Mattay, V. S., T. E. Goldberg, F. Fera, A. R. Hariri, A. Tessitore, M. F. Egan, et al. 2003. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proceed. Natl. Acad. Sci. USA 100:6186-6191.
20. McCrae, R. R., and P. T. Jr. Costa. 1987. Validation of the five-factor model of personality across instruments and observers. J. Pers. Soc. Psychol. 52:81-90.
21. Meyer-Lindenberg, A., P. D. Kohn, B. Kolachana, S. Kippenhan, A. McInerney-Leo, R. Nussbaum, et al. 2005. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 8:594-596.
22. Mitsikostas, D. D., L. I. Mantonakis, and N. G. Chalarakis. 2011. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 31:550-561.
23. Palmatier, M. A., A. M. Kang, and K. K. Kidd. 1999. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol. Psychiatry 46:557-567.
24. Pilowsky, I. 1967. Dimensions of hypochondriasis. Br. J. Psychiatry 113:89-93.
25. Reidenberg, M. M., and D. T. Lowenthal. 1968. Adverse nondrug reactions. N. Engl. J. Med. 279:678-679.
26. Rief, W., J. Avorn, and A. J. Barsky. 2006. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch. Intern. Med. 166:155-160.
27. Rodriguez, S., T. R. Gaunt, and I. N. Day. 2009. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169:505-514.
28. Skotzko, C. E. 2009. Symptom perception in CHF: (why mind matters). Heart Fail. Rev. 14:29-34.
29. Somers, S. C., and A. Lembo. 2003. Irritable bowel syndrome: evaluation and treatment. Gastroenterol. Clin. North Am. 32:507-529.
30. Stein, M. B., M. D. Fallin, N. J. Schork, and J. Gelernter. 2005. COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology 30:2092-2102.
31. Wells, R. E., and T. J. Kaptchuk. 2012. To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am. J. Bioeth. 12:22-29.
32. Wendt, L., A. Albring, S. Benson, H. Engler, A. Engler, A. Hinney, et al. 2014. Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses. PloS One 9:e107665.